Lipella pharmaceuticals delivers late-breaking presentation at the american urological association annual meeting

Presentation focused on positive results from recent phase 2a study pittsburgh , may 1, 2023 /prnewswire/ -- lipella pharmaceuticals inc. (nasdaq: "lipo") ("lipella," "our, "us" or the "company"), a clinical-stage biotechnology company addressing serious diseases with significant unmet need, today announced that it has delivered a late-breaking presentation at the annual meeting of the american urological association (aua) annual meeting in chicago on april 30, 2023. the phase 2a study data was presented by dr. jason hafron, principal investigator for lipella's national trial, and a urologist specializing in the minimally invasive treatment of cancers involving the prostate, kidney and bladder, utilizing robotic surgery.
LIPO Ratings Summary
LIPO Quant Ranking